Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus TRYNGOLZA AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus TRYNGOLZA AUTOINJECTOR.
IMPOYZ vs TRYNGOLZA (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Selective inhibitor of protein kinase C theta (PKCθ), reducing T cell activation and cytokine production.
100 mg orally twice daily
0.5 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 21 days (range 14–28 days), consistent with slow clearance from plasma due to target-mediated drug disposition.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. <1% excreted unchanged in urine.
Category C
Category C
Unknown
Unknown